Molecular Biology Reports

, Volume 27, Issue 3, pp 157–165

Characterization of human and mouse H19 regulatory sequences

Authors

  • Gabriel Banet
    • Department of Pathology and Laboratory MedicineUniversity of Pennsylvania Medical Center
  • Osnat Bibi
    • Department of Biological Chemistry, The Silberman Institute of Life SciencesThe Hebrew University
  • Imad Matouk
    • Department of Biological Chemistry, The Silberman Institute of Life SciencesThe Hebrew University
  • Suhail Ayesh
    • Department of Biological Chemistry, The Silberman Institute of Life SciencesThe Hebrew University
  • Morris Laster
    • Department of Biological Chemistry, The Silberman Institute of Life SciencesThe Hebrew University
  • Katherine Molner Kimber
    • Department of Pathology and Laboratory MedicineUniversity of Pennsylvania Medical Center
  • Mark Tykocinski
    • Department of Pathology and Laboratory MedicineUniversity of Pennsylvania Medical Center
  • Nathan de Groot
    • Department of Biological Chemistry, The Silberman Institute of Life SciencesThe Hebrew University
  • Abraham Hochberg
    • Department of Biological Chemistry, The Silberman Institute of Life SciencesThe Hebrew University
  • Patricia Ohana
    • Department of Biological Chemistry, The Silberman Institute of Life SciencesThe Hebrew University
Article

DOI: 10.1023/A:1007139713781

Cite this article as:
Banet, G., Bibi, O., Matouk, I. et al. Mol Biol Rep (2000) 27: 157. doi:10.1023/A:1007139713781

Abstract

H19 is expressed in a large percentage of bladder tumors, but not expressed in healthy bladder tissue. The aim of this study is to define H19 optimal transcriptional regulatory sequences in tumor cells, which can potentially be used to control expression of a toxin gene in constructs to be used in bladder cancer gene therapy trials in mice and human. Transient expression assays revealed that elements responsible for promoter activity are contained within the 85 bp upstream region. The transcriptional activity of this region was strongly inhibited by the methylation of the Hpa II sites. A modest cell specificity is conferred by the upstream sequences. The human and murine promoter activities were significantly increased by the human H19 4.1 kb enhancer sequence. The 85 bp H19 upstream region contains all the elements to interact with the enhancer. We showed that the human H19 promoter is highly active in a murine bladder carcinoma cell line, justifying its use to drive the expression of a cytotoxin gene in gene therapy trials in mice.

bladder carcinomaH19 geneH19 regulatory sequences
Download to read the full article text

Copyright information

© Kluwer Academic Publishers 2000